https://www.selleckchem.com/pr....oducts/itacitinib-in
9 p 0.01). We also found a tendency to increase the use of oDMTs after a first switch (P1 45.5%, P2 60.1% and P3 78.3%). Multivariate analysis showed that disease evolution (OR=1.06, p=0.04), and year of treatment initiation (OR=1.01 p0.01) were independently associated with choice of oDMTs. This study identified an increasing tendency for the use of oDMDs as initial treatment of RMS in relationship with their approval in Argentina. This study identified an increasing tendency for the use of oDMDs as initial treatme
Like
Comment
Share
